CDXC ChromaDex Corporation Stock Quote

Your browser is no longer supported. Please, upgrade your browser.

publish chart | save to portfolio | create alert

Settings

CDXC [NASD]

ChromaDex Corporation

Healthcare | Biotechnology | USA

statements

Index	-	P/E	-	EPS (ttm)	-0.51	Insider Own	2.30%	Shs Outstand	59.78M	Perf Week	0.59%
Market Cap	325.33M	Forward P/E	-	EPS next Y	-0.17	Insider Trans	0.00%	Shs Float	36.62M	Perf Month	13.84%
Income	-29.70M	PEG	-	EPS next Q	-0.11	Inst Own	21.10%	Short Float	6.57%	Perf Quarter	-4.32%
Sales	50.60M	P/S	6.43	EPS this Y	7.00%	Inst Trans	0.68%	Short Ratio	6.64	Perf Half Y	27.18%
Book/sh	0.28	P/B	18.21	EPS next Y	58.50%	ROA	-72.70%	Target Price	7.06	Perf Year	17.51%
Cash/sh	0.21	P/C	23.92	EPS next 5Y	-	ROE	-149.90%	52W Range	2.50 - 5.80	Perf YTD	18.33%
Dividend	-	P/FCF	-	EPS past 5Y	-30.00%	ROI	-	52W High	-12.24%	Beta	1.65
Dividend %	-	Quick Ratio	1.20	Sales past 5Y	24.80%	Gross Margin	56.90%	52W Low	103.60%	ATR	0.23
Employees	110	Current Ratio	2.00	Sales Q/Q	43.00%	Oper. Margin	-56.90%	RSI (14)	53.42	Volatility	4.17% 5.23%
Optionable	Yes	Debt/Eq	0.01	EPS Q/Q	34.50%	Profit Margin	-58.70%	Rel Volume	0.35	Prev Close	5.10
Shortable	Yes	LT Debt/Eq	0.00	Earnings	-	Payout	-	Avg Volume	362.41K	Price	5.09
Recom	1.50	SMA20	-0.02%	SMA50	7.18%	SMA200	23.66%	Volume	57,095	Change	-0.20%

Oct-16-19

Initiated

Oppenheimer

Outperform

Feb-14-19

Initiated

B. Riley FBR

Buy

Nov-27-17

Resumed

H.C. Wainwright

Buy

$6 → $8

Sep-25-17

Initiated

Ladenburg Thalmann

Buy

Jan-03-17

Initiated

Rodman & Renshaw

Buy

Aug-05-20 09:00AM	LD Micro - Announces Preliminary List of Presenters for the LD-500 ACCESSWIRE
Jul-30-20 12:33PM	Will ChromaDex (CDXC) Report Negative Earnings Next Week? What You Should Know Zacks
Jul-28-20 06:32AM	ChromaDex to Report Second Quarter 2020 Financial Results on Thursday, August 6, 2020 Business Wire
Jul-16-20 06:33AM	New Preclinical Study Finds Niagen® Corrects Social Deficits in Mouse Model of Autism Business Wire
Jul-14-20 06:32AM	ChromaDex External Research Program (CERP) Achieves 200th Material Transfer Agreement for Niagen® (Nicotinamide Riboside) Research Business Wire
Jul-09-20 06:36AM	ChromaDex Announces New Study Results Highlighting Promising Anti-Viral Effects of Niagen® in Coronavirus Cell Model Business Wire
Jul-07-20 06:34AM	ChromaDex and the NIH-NIAID Rocky Mountain Laboratories Announce Study to Assess the Therapeutic Potential of Niagen® in COVID-19 Animal Models Business Wire
Jun-30-20 06:32AM	New Preclinical Findings Suggest Boosting NAD+ with Niagen® Holds Potential for Slowing Aging Process and Reducing Metabolic Damage Business Wire
Jun-17-20 06:33AM	ChromaDex Research & Development Facility Earns ISO/IEC 17025:2017 Accreditation Business Wire
Jun-16-20 06:32AM	ChromaDex to Present at June 2020 Lytham Partners Virtual Investor Growth Conference Business Wire
02:09AM	ChromaDex Commits to COVID-19 Research Following Promising Initial Preclinical Findings Showing Viral Infections Deplete NAD and SARS-CoV-2-Infected Cells Activate NAD Defense Pathway That Utilizes Nicotinamide Riboside (NR) PR Newswire
Jun-15-20 09:42PM	Edited Transcript of CDXC.OQ earnings conference call or presentation 11-May-20 8:30pm GMT Thomson Reuters StreetEvents
Jun-03-20 06:33AM	First-of-Its-Kind Human Tissue Study Finds Link Between NAD Decline and Alcohol-Related Liver Disease (ArLD) Business Wire
Jun-01-20 06:32AM	ChromaDex to Host Symposium on NAD+ in Human Health and Disease at NUTRITION 2020 LIVE ONLINE Annual Meeting Business Wire
May-27-20 03:15PM	Here is What Hedge Funds Think About ChromaDex Corporation (CDXC) Insider Monkey
06:32AM	ChromaDex to Participate in Panel on Master Files for Dietary Supplements Hosted by the American Conference Institute (ACI) and Council for Responsible Nutrition (CRN) Business Wire
May-21-20 06:32AM	ChromaDex Chief Scientific Advisor Dr. Charles Brenner Receives 2020 National Scientific Achievement Award from the American Society for Nutrition Business Wire
May-12-20 01:01AM	ChromaDex Corporation (CDXC) Q1 2020 Earnings Call Transcript Motley Fool -5.49%
May-11-20 05:25PM	ChromaDex (CDXC) Reports Q1 Loss, Tops Revenue Estimates Zacks
04:01PM	ChromaDex Corporation Reports First Quarter 2020 Financial Results Business Wire
May-06-20 06:32AM	Ninth Published Human Trial on Niagen® Nicotinamide Riboside (NR) Shows Increase in NAD+ Levels, Additional Research Highlights Downfalls of Nicotinamide Mononucleotide (NMN) Business Wire
May-01-20 06:32AM	ChromaDex to Report First Quarter 2020 Financial Results on Monday, May 11, 2020 Business Wire
Apr-28-20 06:33AM	Cellular Health Market Leader Tru Niagen® to Launch in U.K. Online and in Retail Stores Exclusively with Superdrug, Expanding Global Retail Partnership Between ChromaDex and A.S. Watson Group Business Wire
Apr-27-20 06:47AM	We're Hopeful That ChromaDex (NASDAQ:CDXC) Will Use Its Cash Wisely Simply Wall St. +8.61%
Apr-24-20 08:47AM	ChromaDex (CDXC) Jumps: Stock Rises 7.7% Zacks
Apr-23-20 06:32AM	ChromaDex and Watsons Launch New Tru Niagen® Beauty Cellular Nutrient in Hong Kong, Broadening Global Retail Partnership Business Wire +7.69%
Apr-20-20 06:32AM	ChromaDex Commits to COVID-19 Research Following Promising Initial Preclinical Findings Showing Viral Infections Deplete NAD and SARS-CoV-2-Infected Cells Activate NAD Defense Pathway That Utilizes Nicotinamide Riboside (NR) Business Wire +11.23%
Apr-14-20 06:32AM	Elysium Health, Inc. Loses Appeal of Patent Challenge Decision, Upholding Validity of ChromaDex Intellectual Property Business Wire
Mar-23-20 06:30AM	Cellular Health Market Leader Tru Niagen® Launches Online in Australia GlobeNewswire -7.30%
Mar-16-20 07:32AM	Edited Transcript of CDXC earnings conference call or presentation 10-Mar-20 8:30pm GMT Thomson Reuters StreetEvents -12.28%
Mar-13-20 06:57AM	US$7.38: That's What Analysts Think ChromaDex Corporation Is Worth After Its Latest Results Simply Wall St.
Mar-12-20 04:44PM	ChromaDex Corrects Statements Made by an Unaffiliated Third Party Regarding its Product and COVID-19 GlobeNewswire -9.78%
Mar-10-20 05:15PM	ChromaDex (CDXC) Reports Q4 Loss, Tops Revenue Estimates Zacks
04:01PM	CHROMADEX CORPORATION REPORTS 2019 FINANCIAL RESULTS GlobeNewswire
02:30PM	Chromadex Corp. to Host Earnings Call ACCESSWIRE
Mar-03-20 12:30PM	ChromaDex (CDXC) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release Zacks
Feb-27-20 06:30AM	New Niagen® Nicotinamide Riboside (NR) Study Deepens Understanding of NAD Decline and Hearing Loss in Animal Model GlobeNewswire
Feb-25-20 06:30AM	ChromaDex to Report Fourth Quarter 2019 Financial Results on Tuesday, March 10, 2020 GlobeNewswire -14.97%
Feb-12-20 06:30AM	ChromaDex Partners with Personalized Nutrition Company, Persona Nutrition, Expanding Global Partnership with Nestlé Health Science GlobeNewswire
Feb-03-20 06:30AM	ChromaDex Launches New Line of High Purity Cannabinoid (CBD) Reference Standards Available for Research and Analytical Testing Worldwide GlobeNewswire
Jan-15-20 06:30AM	ChromaDex Achieves New Regulatory Milestones in the European Union & Australia GlobeNewswire
Jan-06-20 06:30AM	First-of-its-Kind Clinical Study Initiated to Investigate Potential Benefits of Nicotinamide Riboside Combined with Exercise in Older Adults with Hypertension GlobeNewswire +6.83%
Dec-30-19 02:01PM	Should ChromaDex (NASDAQ:CDXC) Be Disappointed With Their 69% Profit? Simply Wall St.
Dec-23-19 10:24AM	Hedge Funds Have Never Been More Bullish On ChromaDex Corporation (CDXC) Insider Monkey
Dec-16-19 06:30AM	ChromaDex Wins Nutritional Outlooks 2019 Best of Industry Ingredient Supplier Award for Niagen® GlobeNewswire -7.38%
Dec-11-19 06:30AM	ChromaDex Launches Tru Niagen® Pro 500, the Largest Serving of Patented Nicotinamide Riboside Available Worldwide GlobeNewswire
Dec-05-19 06:30AM	ChromaDex and Matakana Announce Expanded Retail Partnership in Australia & New Zealand GlobeNewswire
Dec-02-19 06:30AM	ChromaDex Receives Approval for Nicotinamide Riboside Chloride as an Ingredient for Complementary Medicines from the Australian Therapeutic Goods Administration (TGA) GlobeNewswire
Dec-01-19 10:27PM	Edited Transcript of CDXC earnings conference call or presentation 12-Nov-19 9:30pm GMT Thomson Reuters StreetEvents
Nov-20-19 06:30AM	European Commission Votes in Favor on Nicotinamide Riboside Chloride as a Novel Food GlobeNewswire +8.05%
Nov-12-19 07:55PM	ChromaDex (CDXC) Reports Q3 Loss, Tops Revenue Estimates Zacks
04:01PM	ChromaDex Corporation Reports Third Quarter 2019 Financial Results GlobeNewswire
Nov-11-19 08:38AM	Does Market Volatility Impact ChromaDex Corporation's (NASDAQ:CDXC) Share Price? Simply Wall St.
Nov-05-19 10:31AM	Will ChromaDex (CDXC) Report Negative Earnings Next Week? What You Should Know Zacks
Nov-04-19 06:30AM	ChromaDex to Report Third Quarter 2019 Financial Results on Tuesday, November 12, 2019 GlobeNewswire
Oct-31-19 06:30AM	Tru Niagen® Wins Most Favourite Brand Award Among Watsons Hong Kong Loyalty Members GlobeNewswire
Oct-30-19 10:34AM	ChromaDex (CDXC) May Report Negative Earnings: Know the Trend Ahead of Q3 Release Zacks
Oct-17-19 06:30AM	New Study Demonstrates a Unique Role of Nicotinamide Riboside Over Other NAD Precursors GlobeNewswire
Oct-11-19 06:30AM	ChromaDex Statement Regarding the October 9th Order in the Central District of California Litigation GlobeNewswire
Oct-07-19 06:30AM	Humanitarian Grant Awarded for Preclinical Study on the Impact of NAD Precursor Vitamins on Milk Bioactive Production and Brain Development in Rodents GlobeNewswire
Sep-26-19 06:30AM	ChromaDex to Present at the 5th Annual B. Riley FBR Consumer and Media Conference GlobeNewswire
Sep-10-19 08:00AM	Industry Leaders Aubrey De Grey And Frank Jaksch Join Yuva Biosciences Advisory Board PR Newswire
Aug-15-19 10:16PM	Edited Transcript of CDXC earnings conference call or presentation 7-Aug-19 8:30pm GMT Thomson Reuters StreetEvents
Aug-14-19 09:10AM	ChromaDex Announces $7 Million Private Placement of Common Stock GlobeNewswire
Aug-08-19 12:34AM	ChromaDex Corporation (CDXC) Q2 2019 Earnings Call Transcript Motley Fool
Aug-07-19 07:05PM	ChromaDex (CDXC) Reports Q2 Loss, Tops Revenue Estimates Zacks
04:10PM	ChromaDex Receives Positive Opinion on Nicotinamide Riboside as a Novel Food from the World-Leading European Food Safety Authority (EFSA) GlobeNewswire
04:01PM	ChromaDex Corporation Reports Second Quarter 2019 Financial Results GlobeNewswire
Aug-06-19 04:05PM	ChromaDex Adds Top Talent to its Leadership Team GlobeNewswire
Aug-01-19 10:33AM	ChromaDex (CDXC) May Report Negative Earnings: Know the Trend Ahead of Q2 Release Zacks
Jul-31-19 04:05PM	ChromaDex to Report Second Quarter 2019 Financial Results on Wednesday, August 7, 2019 GlobeNewswire
Jul-24-19 06:30AM	TRU NIAGEN® Expands Canadian Retail Footprint with Distribution at Whole Foods Ontario Locations GlobeNewswire
Jul-23-19 06:30AM	ChromaDex Appoints Scripps Research Professor of Molecular Medicine, Brunie H. Felding, PhD, to the Scientific Advisory Board GlobeNewswire
Jul-08-19 09:29AM	ChromaDex Shares Nicotinamide Riboside Study Results Benzinga
06:30AM	Newly Published Nicotinamide Riboside Study Further Demonstrates Safety of Sustained Niagen Supplementation and Optimal Dosing Levels GlobeNewswire
Jun-05-19 06:30AM	TRU NIAGEN® Awarded Ingredient of the Year: Healthy Aging by NutraIngredients-USA GlobeNewswire
May-24-19 05:24AM	Edited Transcript of CDXC earnings conference call or presentation 9-May-19 8:30pm GMT Thomson Reuters StreetEvents
May-15-19 04:01PM	ChromaDex to Present at the 20th Annual B. Riley FBR Investor Conference GlobeNewswire
May-13-19 01:18PM	ChromaDex Corporation (CDXC) Q1 2019 Earnings Call Transcript Motley Fool
May-09-19 06:45PM	ChromaDex (CDXC) Reports Q1 Loss, Tops Revenue Estimates Zacks
05:38PM	ChromaDex: 1Q Earnings Snapshot Associated Press
04:01PM	ChromaDex Corporation Reports First Quarter 2019 Financial Results GlobeNewswire
08:20AM	ChromaDex Announces $10 Million Issuance of Convertible Notes GlobeNewswire
May-07-19 11:13AM	Should You Be Concerned About ChromaDex Corporation's (NASDAQ:CDXC) Historical Volatility? Simply Wall St.
May-02-19 10:32AM	Will ChromaDex (CDXC) Report Negative Q1 Earnings? What You Should Know Zacks
06:30AM	ChromaDex to Report First Quarter 2019 Financial Results on Thursday, May 9, 2019 GlobeNewswire
Apr-24-19 06:30AM	ChromaDex Furthers TRU NIAGEN® Global Expansion in Canada with WELL Health Technologies GlobeNewswire
Apr-15-19 06:30AM	ChromaDex Drives Global Expansion Strategy for TRU NIAGEN® with Specialty Retail Launch and Expanded eCommerce Distribution in Canada GlobeNewswire
Apr-09-19 06:30AM	New Study Deepens Research Into the Potential Cardiovascular Health Benefits of Supplementation with Nicotinamide Riboside (NR) GlobeNewswire
06:30AM	New Study Deepens Research Into the Potential Cardiovascular Health Benefits of Supplementation with Nicotinamide Riboside (NR) Business Wire
Apr-05-19 10:55AM	Volatility 101: Should ChromaDex (NASDAQ:CDXC) Shares Have Dropped 17%? Simply Wall St.
Apr-03-19 06:30AM	Dr. Charles Brenner, Discoverer of Nutrient Nicotinamide Riboside as a Vitamin, Announced as Speaker at Upgrade XPs Sixth Annual Biohacking Conference GlobeNewswire
Apr-01-19 08:40AM	Consolidated Research: 2019 Summary Expectations for Vishay Intertechnology, Belmond, Silicon Motion Technology, Ardmore Shipping, Northwest Pipe, and ChromaDex Fundamental Analysis, Key Performance Indications GlobeNewswire
Mar-13-19 02:01AM	Edited Transcript of CDXC earnings conference call or presentation 7-Mar-19 9:30pm GMT Thomson Reuters StreetEvents
Mar-11-19 04:01PM	ChromaDex to Present at the 31st Annual ROTH Conference GlobeNewswire
Mar-08-19 06:30AM	ChromaDex Brings TRU NIAGEN® to SXSW® 2019 GlobeNewswire
Mar-07-19 04:01PM	ChromaDex Corporation Reports 2018 Financial Results GlobeNewswire
Mar-01-19 06:30AM	ChromaDex to Present at the 39th Annual Cowen Health Care Conference GlobeNewswire
Feb-28-19 06:30AM	ChromaDex to Report Fourth Quarter 2018 Financial Results on Thursday, March 7, 2019 GlobeNewswire
Feb-22-19 10:34AM	Why ChromaDex Corporation (NASDAQ:CDXC) Could Be Worth Watching Simply Wall St.

ChromaDex Corporation operates as a nutraceutical company. The company offers Nicotinamide riboside (NIAGEN), a novel form of vitamin B3 for enhancing nicotinamide adenine dinucleotide (NAD) level used for healthy aging; and Immulina, a spirulina extract and compound, which is used for improving human immune function. It also provides reference standards and fine chemicals to conduct quality control of raw materials and consumer products in dietary supplements, cosmetics, food and beverages, and pharmaceutical industries. The company markets and sells its products directly in the United States and Canada; and through international distributors. ChromaDex Corporation is headquartered in Los Angeles, California.

open in yahoo | open in reuters | open in google

Upgrade your FINVIZ experience